SGHT - Sight Sciences, Inc. So'nggi Yangiliklar | Finranks

06.08.2026

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

06.08.2026

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.

05.08.2026

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

05.08.2026

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

05.08.2026

Sight Sciences Reports Second Quarter 2026 Financial Results

Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance

04.08.2026

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
SGHT	UBS	Buy	undefined >> $7	July 28th 2026

Press-relizlar

05.08.2026

Sight Sciences Reports Second Quarter 2026 Financial Results

Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance

Sight Sciences, Inc. (SGHT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Sight Sciences, Inc. (SGHT)

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Search stocks

Sight Sciences, Inc. (SGHT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Sight Sciences, Inc. (SGHT)

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System